Biocon's latest updates:

Upcoming Results & Weight-Loss Drug Strategy: Biocon's Q1 FY26 financial results are due on August 7, 2025. A key focus for the company is the weight-loss and diabetes market, with plans to be an early entrant for generic Ozempic and Wegovy (semaglutide biosimilars). They are actively seeking Canadian approval for generic Ozempic by September 2025 for a 2026 launch but have withdrawn plans for China due to intense local competition. Phase 3 trials for semaglutide in India are expected to begin soon, aiming for a late 2026 approval. Recent Biosimilar Approvals & Launches: Biocon Biologics continues to expand its biosimilar portfolio. Health Canada approved Yesafili™ (aflibercept biosimilar) on June 26, 2025, with its first global launch scheduled for Canada on July 4, 2025. This marks their 10th commercialized biosimilar. Additionally, the U.S. FDA approved Jobevne™ (bevacizumab biosimilar) in April 2025, and Yesintek™ (ustekinumab biosimilar), approved in December 2024, launched in the US in February 2025 and has secured significant market access. Biocon Pharma also received Indian approval for diabetes drug Liraglutide in June 2025. Strategic Collaborations & Milestones: Biocon's Malaysian subsidiary has supplied over 100 million recombinant human insulin cartridges to Malaysia's Ministry of Health, demonstrating its commitment to diabetes care in the region. They have also partnered with the National Cancer Society of Malaysia to improve cancer patients' access to affordable biosimilars and collaborated with Eris Lifesciences in India to expand product access in key therapeutic areas.